White Paper - HAI Treatments: A Challenging Market

Given the attention focused on hospital-acquired infections (HAIs), one would think there would be a thriving market for pharmaceutical products to combat this scourge. And there is a fairly large-sized market - over $8.06 billion earned in 2010 by companies selling pharmaceutical treatments. But it is a market that has seen declines for a variety of reasons, and even as the greatest threats emerge, it may take a few years to recover revenues lost to patent challenges.

Infections contracted in hospitals, also known as nosocomial infections, are the fourth largest killer in the United States. Considering the 40 million hospital admissions each year in the United States, this provides a nosocomial infection rate of 5% of admissions.

View the complete White Paper